Bring the problem. Leave with answers.

What would the visit actually involve?

A visit may involve a live talk or an exchange of messages. The care must still meet the same requirements as a visit in person.

Ask how the assessment works, who reviews your history, and how you can talk back if something is unclear.

Medical board guidance calls for enough history and a way for the person assessing you to ask follow-up questions.

The online assessment methods allowed under state rules vary from state to state, as of September 2026.

Ask the service which approach applies where you will be.

Can I ask the person assessing me follow-up questions?

Under the medical boards’ May 2026 guidance, patients must be able to ask their treating professional follow-up questions.

Ask how to raise a new concern after the visit, who reads it, and what happens if an in-person exam is needed.

That guidance is a model for state boards; it is not a single nationwide law.

What evidence applies to my problem?

Ask which human study matches the problem being treated. Ask what it measured and whether it had a comparison group.

As of September 2026, the small human studies reviewed by the Food and Drug Administration (FDA) do not prove that BPC-157 treats injuries.

Ask what other options fit your goal, and what further assessment would help compare them.

What exactly is being proposed?

Ask who makes the product and whether it has Food and Drug Administration (FDA) approval.

Ask for the ingredient’s full name.

The FDA found that sellers use the BPC-157 name for substances with different chemical makeups. The substance you receive might not match the one your doctor ordered.

Ask for those details in writing. Keep them with the licence checks and cost quote.